Researchers have achieved a significant milestone in vaccine development with a virus-like particle (VLP) candidate that successfully generated protective antibodies against enterovirus D68 (EV-D68) in nonhuman primate trials. The experimental vaccine, detailed in Science Translational Medicine, represents the first specific prevention tool targeting a virus responsible for recurring outbreaks of severe respiratory illness and acute flaccid myelitis—a polio-like paralysis condition affecting primarily children.
The vaccine’s innovative approach uses viral particles that structurally mimic EV-D68 without containing infectious genetic material. By targeting receptor binding sites essential for viral cell entry, the vaccine induced neutralizing antibodies capable of blocking viral attachment and infection. This mechanism offers a direct intervention against a pathogen that has cycled through biennial outbreaks since 2014, with particularly concerning surges of paralysis cases in 2016. The findings provide a foundation for advancing this candidate toward human clinical trials and potentially addressing a critical gap in pediatric infectious disease prevention.
Read the full article on GMJ Newsroom.
Was this article helpful?
